Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022, 166(2):150-154 | DOI: 10.5507/bp.2022.008
Warfarin involvement, in comparison to NOACs, in the development of systemic atherosclerosis
- Faculty of Medicine, "Lucian Blaga" University of Sibiu, Romania
Adverse effects of drugs are one of the objective criteria used for choosing the most appropriate anticoagulant. It is worrying that warfarin may be involved in the progression of systemic atherosclerosis, as more and more articles suggest. Warfarin has been widely used in the past and has greater efficacy compared to dabigatran in patients with mechanical heart valves; there is an antidote to it and it is cheap. Unfortunately, warfarin inhibits the synthesis and activity of Matrix-Gla-Protein, which is the major vitamin K-dependent inhibitor of arterial calcification - an active process associated with atherosclerosis, stimulated by inflammatory mechanisms. Vitamin K antagonizes the NF-κB signaling mechanism and contributes to the prevention of arterial calcifications. Warfarin given in experimental animal models of atherosclerosis contributed to the occurrence of an increased number of aortic calcifications. Warfarin treatment used in clinical trials was associated with the progressive increase of coronary atheroma calcification. Younger patients are more sensitive to warfarin-related arterial calcifications compared to older patients, due to warfarin-induced cellular senescence changes. Non-vitamin K antagonist direct oral anticoagulants do not interact with vitamin K. Edoxaban reduces the inflammatory process in the vascular walls and the proliferation of smooth vascular muscle cells, so it is involved in the prevention of vascular maladaptive remodeling process. Apixaban is able to stabilize the coronary atherosclerotic process. Randomized clinical trials are needed to evaluate the impact of warfarin on plaque stability and cardiovascular evolution of patients.
Keywords: atherosclerosis, direct oral anticoagulants, thrombosis, vascular calcification, warfarin
Received: October 31, 2021; Revised: February 7, 2022; Accepted: February 8, 2022; Prepublished online: February 18, 2022; Published: May 13, 2022 Show citation
References
- Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood 2020;135(5):351-9.
Go to original source...
Go to PubMed...
- Jaffer IH, Fredenburgh JC, Stafford A, Whitlock RP, Weitz JI. Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. Ann Thorac Surg 2020;110(2):582-90.
Go to original source...
Go to PubMed...
- Shioi A, Morioka T, Shoji T, Emoto M. The Inhibitory Roles of Vitamin K in Progression of Vascular Calcification. Nutrients 2020;12(2):583.
Go to original source...
Go to PubMed...
- Siltari A, Vapaatalo H. Vascular Calcification, Vitamin K and Warfarin Therapy - Possible or Plausible Connection? Basic Clin Pharmacol Toxicol 2018;122(1):19-24.
Go to original source...
Go to PubMed...
- Win TT, Nakanishi R, Osawa K, Li D, Susaria SS, Jayawardena E, Hamal S, Kim M, Broersen A, Kitslaar PH, Dailing C, Budoff MJ. Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial). Am Heart J 2019;212:129-33.
Go to original source...
Go to PubMed...
- Lee J, Nakanishi R, Li D, Shaikh K, Shekar C, Osawa K, Nezarat N, Jayawardena E, Blanco M, Chen M, Sieckert M, Nelson E, Billingsley D, Hamal S, Budoff MJ. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. Am Heart J 2018;206:127-30.
Go to original source...
Go to PubMed...
- Rattazzi M, Faggin E, Bertacco E, Nardin C, Pagliani L, Plebani M, Cinetto F, Guidolin D, Puato M, Pauletto P. Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice. Cardiovasc Ther 2018;36(4):e12438.
Go to original source...
Go to PubMed...
- Millenaar D, Bachmann P, Böhm M, Custodis F, Schirmer SH. Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth. Vascul Pharmacol 2020;127:106661.
Go to original source...
Go to PubMed...
- Osawa K, Nakanishi R, Win TT, Li D, Rahmani S, Nezarat N, Sheidaee N, Budoff MJ. Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression. Clin Cardiol 2017;40(10):807-13.
Go to original source...
Go to PubMed...
- Andrews J, Psaltis PJ, Bartolo BAD, Nicholls SJ, Puri R. Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends Cardiovasc Med 2018;28(8):491-501.
Go to original source...
Go to PubMed...
- Li M, Wang Z, Shao J, Li S, Xia H, Yu L, Hu Z. Captopril Attenuates the Upregulated Connexin 43 Expression in Artery Calcification. Arch Med Res 2020;51(3):215-23.
Go to original source...
Go to PubMed...
- Seime T, Akbulut AC, Liljeqvist ML, Siika A, Jin H, Winski G, van Gorp RH, Karlöf E, Lengquist M, Buckler AJ, Kronqvist M, Waring OJ, Lindeman JHN, Biessen EAL, Maegdefessel L, Razuvaev A, Schurgers LJ, Hedin U, Matic L. Proteoglycan 4 Modulates Osteogenic Smooth Muscle Cell Differentiation during Vascular Remodeling and Intimal Calcification. Cells 2021;10(6):1276.
Go to original source...
Go to PubMed...
- Florea A, Sigl JP, Morgenroth A, Vogg A, Sahnoun S, Winz OH, Bucerius J, Schurgers LJ, Mottaghy FM. Sodium [18F]Fluoride PET Can Efficiently Monitor In Vivo Atherosclerotic Plaque Calcification Progression and Treatment. Cells 2021;10(2):275.
Go to original source...
Go to PubMed...
- Andrews J, Psaltis PJ, Bayturan O, Shao M, Stegman B, Elshazly M, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ, Puri R. Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound. JACC Cardiovasc Imaging 2018;11(9):1315-23.
Go to original source...
Go to PubMed...
- Uto K, Yoshizawa S, Aoki C, Nishikawa T, Oda H. Inhibition of extracellular matrix integrity attenuates the early phase of aortic medial calcification in a rodent model. Atherosclerosis 2021;319:10-20.
Go to original source...
Go to PubMed...
- Lin JF, Fan LL, Li BW, Zhao RR, Jiang LG, Zhang BC, Lu YS, Shao JW. A study to evaluate herb-drug interaction underlying mechanisms: An investigation of ginsenosides attenuating the effect of warfarin on cardiovascular diseases. Eur J Pharm Sci 2020;142:105100.
Go to original source...
Go to PubMed...
- Chan NC, Eikelboom JW. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood 2019;133(21):2269-78.
Go to original source...
Go to PubMed...
- Namba S, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Hashikata T, Kitasato L, Hashimoto T, Kameda R, Meguro K, Shimohama T, Tojo T, Ako J. Erratum to: Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels 2017;32(8):983.
Go to original source...
Go to PubMed...
- Santiago MB, Paz A. Acute Peripheral and/or Cutaneous Ischemic Syndrome: What Rheumatologists Should Know. J Clin Rheumatol 2021;27(2):73-9.
Go to original source...
Go to PubMed...
- De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost 2019;119(1):14-38.
Go to original source...
Go to PubMed...
- Cappato R, Chiarito M, Giustozzi M, Briani M, Ali H, Riva L, Bonitta G, Lodigiani C, Furlanello F, Balla C, Lupo P, Stefanini G. Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis. Eur J Intern Med 2021;83:14-20.
Go to original source...
Go to PubMed...
- Feuring M, Schulman S, Eriksson H, Kakkar AJ, Schellong S, Hantel S, Schueler E, Kreuzer J, Goldhaber SZ. Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™. J Thromb Thrombolysis 2017;43(4):484-9.
Go to original source...
Go to PubMed...
- Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vasc Med 2016;21(6):506-14.
Go to original source...
Go to PubMed...
- Wei N, Lu L, Zhang H, Gao M, Ghosh S, Liu Z, Qi J, Wang J, Chen J, Huang H. Warfarin Accelerates Aortic Calcification by Upregulating Senescence-Associated Secretory Phenotype Maker Expression. Oxid Med Cell Longev 2020;2020:2043762.
Go to original source...
Go to PubMed...
- van Gorp RH, Dijkgraaf I, Bröker V, Bauwens M, Leenders P, Jennen D, Dweck MR, Bucerius J, Briedé JJ, van Ryn J, Brandenburg V, Mottaghy F, Spronk HMH, Reutelingsperger CP, Schurgers LJ. Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. J Thromb Haemost 2021;19(5):1348-63.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.